You are here: Industry Insights > Fintepla

News List

UCB to buy rare disease therapies developer Zogenix for $1.9bn Pharmaceutical-Technology
January 21, 2022
The company’s subsidiary will be merged into Zogenix and the remaining shares of Zogenix common stock will be cancelled.
EU green light for Zogenix’s Fintepla pharmatimes
December 24, 2020
The European Commission (EC) has approved Zogenix’s Fintepla (fenfluramine) for the treatment of seizures associated with Dravet syndrome.
EMA recommends 10 medicines for approval in October meeting europeanpharmaceuticalreview
October 23, 2020
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
FDA Approves New Therapy for Dravet Syndrome americanpharmaceuticalreview
July 07, 2020
The U.S. Food and Drug Administration (FDA) approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older.
US FDA grants approval of Fintepla to Zogenix expresspharma
June 28, 2020
Fintepla offers an additional effective treatment option for the treatment of seizures associated with Dravet syndrome: Zogenix.
FDA refuses Zogenix’s seizure drug Fintepla pharmatimes
April 11, 2019
The U.S. Food and Drug Administration (FDA) has refused to fully review Zogenix’s marketing application for its seizure drug, Fintepla (ZX008, low-dose fenfluramine).